Back To: Home : Featured Technology : Stem Cell


Coming into the light
April 2012
by Jeffrey Bouley  |  Email the author


BASEL, SwitzerlandóLonza announced in March an agreement with Korean biotechnology company LegoChem Biosciences Inc. for the custom material production of a monoclonal antibody that will be used for in-vivo proof-of-concept studies for their technology platform development.  
Under this agreement, Lonza will produce preclinical material using Light Path Discovery Services at its applied protein services facility in Cambridge, U.K. The deal is important in both the short-term and long-term goals of LegoChem, Lonza's Sze Guan Chu tells ddn.  
"In the short term, LegoChem Biosciences needed custom material in a short timeframe to meet their clinical development timelines," says Chu, who is in the Asia sales and business development arm of Lonza's Development Services operation. As for the long term, "LegoChem Biosciences is in the process of developing a new technology platform and will need material for future proof-of-concept studies."
And as for Lonza's particular strength in this deal, Chu says, "Lonza brings a fully developed and optimized GS Expression System to allow for high titers of material to be delivered in a reduced timeline. LegoChem Biosciences needed someone to produce a relatively large amount of material in a short period of time. Their timeline was a critical factor to the advancement of their development milestones. Lonza's Light Path offering is well-suited to customers that meet this criteria."  
Lonza's Light Path Custom Material Services supports projects in their early phase, providing cGMP product within 11 months, according to the company. In addition, Lonza's Light Path Discovery Service reportedly provides non-GMP product in six to 10 weeks to support customers in the discovery-testing phase. Since the launch of Light Path in early 2011, Lonza says it has seen an increased demand for this offering, which is focused on a reduced timeline to IND filing. Light Path allows customers to reach their clinical milestones more efficiently, the company maintains.
"Lonza's Light Path Discovery Services were specifically designed with the demands of preclinical assessment in mind," said Janet White, head of Lonza's Development Services, in the news release about the deal. "Lonza has built a strong reputation for CMO excellence. Today, we're also focusing efforts on supporting emerging biotechnology innovation at every stage of development to allow each customer the best chance for clinical success."
"We have chosen to work with Lonza on this important project because of their reliability and solid reputation in field of mammalian development," said Dr. Woo Sung Ho, biology director and vice president of LegoChem, in the official statement about the deal. Chu says the two companies have not worked together before, and were introduced through a Korean consultant.
In other recent news from Lonza Development Services, late February saw an announcement of another early-stage development deal, with Lonza and San Diego-based Eclipse Therapeutics Inc. announcing an agreement for the production of Eclipse's novel cancer therapeutic antibody, ET-101, using Light Path Development Services. ET-101 is under investigation for the inhibition of the growth of cancer stem cells. Under the agreement, Lonza will produce Phase I clinical materials at its development and manufacturing facility in Slough, United Kingdom.  

Lonza and Eclipse Therapeutics announce development and manufacturing agreement  
BASEL, SwitzerlandóLonza and Eclipse Therapeutics announced at the end of February an agreement for the production of Eclipse's novel cancer therapeutic antibody, ET-101, using Light Path Development Services.   
ET-101 is a novel therapeutic antibody designed to target cancer stem cells. Eliminating cancer stem cells, in conjunction with other therapies that address the tumor bulk, represents a new cancer treatment paradigm that could offer a distinct advantage over existing strategies, and a solution for chemoresistance, according to Eclipse.  
Under the agreement, Lonza will produce Phase I clinical material at its development and manufacturing facility in Slough, U.K.  
"Lonza's best-in-class antibody manufacturing capabilities will greatly support our development strategy to deliver the highest quality and most effective therapeutics targeting cancer stem cells. Moving into cell-line development and subsequent manufacturing represents an important milestone for Eclipse," says Dr. Christopher Reyes, chief scientific officer of Eclipse.
Code: E041208



1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.